SCHEMBL4965100

SCHEMBL4965100

CN1C(=O)NC2(CCN(CCc3ccc(C(N)=O)cc3)CC2)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 9/20 0.43
OPRD1 P41143 3/20 0.43
OPRK1 P41145 2/20 0.43
ARRB1 P49407 2/20 0.41
HRH3 Q9Y5N1 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR7 P34969 1/20 0.38
HTR6 P50406 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA13 Q8N1Q1 1/20 0.38
CA14 Q9ULX7 1/20 0.38
RAB9A P51151 2/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965108 0.85 SIGMAR1 (0.46) OPRM1HRH3HTR2AHTR2CLMNA
SCHEMBL4756624 0.80 ITGB3 (0.46) OPRM1OPRD1OPRK1ARRB1HTR2A
SCHEMBL4699834 0.76 SIGMAR1 (0.50) HRH3HTR2AHTR2CHTR7HTR6
SCHEMBL6644138 0.75 HRH3 (0.58) HRH3HTR2AHTR2CHTR7HTR6
SCHEMBL2761915 0.74 HRH3 (0.61) HRH3HTR2AHTR2CHTR7HTR6
SCHEMBL2762023 0.74 HRH3 (0.61) HRH3HTR2AHTR2CHTR7HTR6
SCHEMBL4700447 0.73 TSHR (0.48) HTR2AHTR2CHTR7HTR6MAOB
SCHEMBL4699855 0.72 KDM1A (0.43) OPRM1OPRD1OPRK1MAOBKCNH2
SCHEMBL3514227 0.72 THRA (0.53) HRH3HTR2AHTR2CHTR7HTR6
SCHEMBL4703775 0.71 KCNH2 (0.43) OPRM1ARRB1HRH3HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629147-B2 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION (US) 2014-01-14 US disclosed
US-20080207635-A1 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207635-A1 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders LCK, MALT1, MYD88 OPRM1 4013/4885OPRD1 3935/4885OPRK1 2441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.